Genmab (GMAB)
(Delayed Data from NSDQ)
$28.56 USD
-0.51 (-1.75%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $28.54 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.56 USD
-0.51 (-1.75%)
Updated Apr 23, 2024 03:59 PM ET
After-Market: $28.54 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum D VGM
Zacks News
Genmab A/S Sponsored ADR (GMAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Genmab A/S Sponsored ADR (GMAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
New Strong Buy Stocks for January 17th
by Zacks Equity Research
SKWD, PHG, BK, PAGS and GMAB have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2024.
GMAB or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMAB vs. TECH: Which Stock Is the Better Value Option?
HRMY or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HRMY vs. GMAB: Which Stock Is the Better Value Option?
AbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AbbVie's (ABBV) Epcoritamab Gets Approval in Europe for DLBCL
by Zacks Equity Research
Tepkinly is AbbVie's (ABBV) second hematological cancer drug to be approved in the European Union. It is also the third blood cancer medicine in AbbVie's portfolio
Seagen's (SGEN) Late-Stage Cervical Cancer Study Meets Goals
by Zacks Equity Research
Seagen (SGEN) and Genmab announce that the late-stage study of Tivdak in the second-line treatment of adult patients with recurrent or metastatic cervical cancer meets the primary and secondary goals.
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.
Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?
by Zacks Equity Research
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks.com featured highlights Genmab, Hologic, ServiceNow and Splunk
by Zacks Equity Research
Genmab, Hologic, ServiceNow and Splunk have been highlighted in this Screen of The Week article.
4 Top Stocks to Buy on Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on the bottom line in their next releases. These stocks include Genmab (GMAB), Hologic (HOLX), ServiceNow (NOW) and Splunk (SPLK).
GILD or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GILD vs. GMAB: Which Stock Is the Better Value Option?
New Strong Buy Stocks for January 11th
by Zacks Equity Research
GMAB, OSW, ACDC, EVBG and MTG have been added to the Zacks Rank #1 (Strong Buy) List on January 11 , 2023.
Ensign Group (ENSG) Unveils Dividend Hike to Reward Shareholders
by Zacks Equity Research
Ensign Group's (ENSG) latest dividend hike reflects strong financial standing and intensified focus in the tactical deployment of capital.
LGND or GMAB: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. GMAB: Which Stock Is the Better Value Option?
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.
Genmab AS Sponsored ADR (GMAB) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Genmab AS Sponsored ADR (GMAB) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Ensign Group (ENSG) Facility Buyout to Boost Colorado Foothold
by Zacks Equity Research
Ensign Group (ENSG) acquires two skilled nursing facilities in Colorado that are likely to grow its healthcare portfolio and solidify its nationwide presence.
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner
by Zacks Equity Research
Tap Genmab, KnowBe4, UserTesting, Enphase Energy and Gartner are part of the Zacks Screen of the Week article.
5 Top Stocks to Tap Earnings Beat Potential
by Sanghamitra Saha
Buy shares of Genmab (GMAB), KnowBe4 (KNBE), UserTesting (USER), Enphase Energy (ENPH) and Gartner (IT).
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
by Zacks Equity Research
AbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Its early and mid-stage pipeline has several candidates with blockbuster potential.
Is Elevance Health, Inc. (ELV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Elevance Health (ELV) and Genmab AS Sponsored ADR (GMAB) have performed compared to their sector so far this year.